bucindolol has been researched along with monocrotaline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belló-Klein, A; Bonetto, JHP; Casali, KR; Colombo, R; Donatti, LM; Godoy, AEG; Lima-Seolin, BG; Litvin, IE; Rosa Araujo, ASD; Schenkel, PC; Teixeira, RB | 1 |
| Belló-Klein, A; Bonetto, JHP; Colombo, R; de Lima-Seolin, BG; Fernandes, RO; Godoy, AEG; Hennemann, MM; Khaper, N; Litvin, IE; Sander da Rosa Araujo, A; Schenkel, PC; Teixeira, RB | 1 |
2 other study(ies) available for bucindolol and monocrotaline
| Article | Year |
|---|---|
Bucindolol improves right ventricle function in rats with pulmonary arterial hypertension through the reversal of autonomic imbalance.
Topics: Animals; Autonomic Nervous System; Blood Pressure; Electrocardiography; Heart Ventricles; Hypertension, Pulmonary; Male; Monocrotaline; Propanolamines; Rats; Rats, Wistar; Ventricular Pressure | 2017 |
Bucindolol attenuates the vascular remodeling of pulmonary arteries by modulating the expression of the endothelin-1 A receptor in rats with pulmonary arterial hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Echocardiography; Hypertension, Pulmonary; Male; Monocrotaline; Nitric Oxide Synthase Type III; Oxidative Stress; Propanolamines; Pulmonary Artery; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Vascular Remodeling | 2018 |